Lund, Sweden

Bonesupport is an orthobiologics company focused on developing and commercialising a pipeline of unique injectable drug-eluting, bioceramic bone graft substitutes based on its proprietary CERAMENT technology.

Investment Perspective

Q119 results provide evidence that the strategic initiatives put in place during 2018 are beginning to deliver results. Bonesupport posted a second successive quarter of CERAMENT sales growth and, with various growth drivers gaining traction, this momentum is set to continue during 2019 and beyond. Management are targeting 40%+ revenue growth from 2020 onwards. Key drivers include the expanded global commercial footprint becoming fully operational, leverage of key clinical and health economics data, new product launches (including potentially CERAMENT G in the US in 2021), and continued improvement in market access/reimbursement. We maintain our Bonesupport valuation of SEK39/share (or SEK 2.034bn).

Market information

SymbolPrimary exchangeCurrency
Last PriceMarket Cap
52 Week Low52 Week High


Building momentum
Update | 07 May 2019
Gearing up for growth
Update | 01 Mar 2019
Key CERTiFy study confirms CERAMENT’s properties
Update | 19 Nov 2018

Recent News

Bulletin from the annual shareholders meeting
14 May 2019
Q119 Report
02 May 2019
Change in management team
24 Apr 2019
UK study confirms active remodelling of CERAMENT into human bone
10 Apr 2019